Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee

PHASE2RecruitingINTERVENTIONAL
Enrollment

4,000

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

August 31, 2026

Study Completion Date

August 31, 2026

Conditions
Osteoarthritis
Interventions
BIOLOGICAL

[StroMed + platelet rich plasma (PRP)]

\[Day 0\] - Because no enzymes or drugs are added with this mechanical process, the resulting cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Also Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.

BIOLOGICAL

[PRP] platelet rich plasma

Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 7,14 and 30

BIOLOGICAL

[PRP] platelet rich plasma

Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 30 and 60

Trial Locations (1)

16127

RECRUITING

VivaTech International, Inc., Grove City

All Listed Sponsors
lead

VivaTech International, Inc.

INDUSTRY

NCT02844751 - Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Knee | Biotech Hunter | Biotech Hunter